Front Row Advisors’s Vericel Corp VCEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-104
Closed -$4.77K 829
2024
Q2
$4.77K Sell
104
-18
-15% -$849 ﹤0.01% 737
2024
Q1
$6.35K Buy
+122
New +$5.35K ﹤0.01% 685
2023
Q4
Sell
-102
Closed -$3.42K 796
2023
Q3
$3.42K Hold
102
﹤0.01% 745
2023
Q2
$4K Buy
102
+2
+2% +$66 ﹤0.01% 728
2023
Q1
$3K Sell
100
-3
-3% -$87 ﹤0.01% 787
2022
Q4
$3K Hold
103
﹤0.01% 754
2022
Q3
$2K Buy
103
+26
+34% +$709 ﹤0.01% 842
2022
Q2
$2K Buy
77
+6
+8% +$177 ﹤0.01% 852
2022
Q1
$3K Buy
+71
New +$2.56K ﹤0.01% 825

Other funds holding VCEL

Front Row Advisors's VCEL Position: Q3 2024 in Review

Front Row Advisors sold out of Vericel Corp (VCEL) in Q3 2024, closing a stake of 104 shares — an estimated $4.77K sold.

Front Row Advisors first reported a position in VCEL in Q1 2022 and held it in 9 quarters. The position peaked at $6.35K in Q1 2024. 268 funds tracked by Wall St. Rank hold VCEL as of Q3 2024.

  • Front Row Advisors reported no remaining Vericel Corp position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 104 Vericel Corp shares in Q3 2024, an estimated $4.77K.
  • Front Row Advisors first reported a position in Vericel Corp in Q1 2022 and held it in 9 quarters.
  • Front Row Advisors's Vericel Corp position peaked at $6.35K in Q1 2024.
  • 268 funds tracked by Wall St. Rank held Vericel Corp as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.